Trial Profile
A phase II study investigating efficacy and safety of low dosage re-treatment with (177)Lu-DOTATATE (Lu-PRRT) in patients with gastroenteropancreatic neuroendocrine neoplasms who relpased after treatment with (90)Y-DOTATOC (Y-PRRT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2016
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroepithelial neoplasms
- Focus Adverse reactions; Therapeutic Use
- 22 Oct 2016 New trial record